A Look At India’s Key Pharmaceutical Patent CasePublished on 7 August 2012 @ 8:32 pm
Intellectual Property Watch
This month, the Indian Supreme Court will hear final arguments in a challenge by the pharmaceutical company Novartis against the Indian Patent Office’s rejection of a patent for the leukemia drug, Glivec. The Court’s ruling will have profound implications for pharmaceutical patenting in India, and more generally how countries with newly introduced pharmaceutical patent regimes limit “evergreening” of existing molecules and patent portfolios.
Writing in Science, Bhaven Sampat, Kenneth Shadlen, Tahir Amin discuss the implications of the case. The article examines the peculiarities of the Glivec case itself, reviews alternative approaches to combatting evergreening, and analyses the Indian approach.
The article is found here.
A pdf of the article may be requested by emailing firstname.lastname@example.org.